NF-κB in cancer therapy
MetadataShow full item record
The transcription factor nuclear factor kappa B (NF-κB) has attracted increasing attention in the field of cancer research from last few decades. Aberrant activation of this transcription factor is frequently encountered in a variety of solid tumors and hematological malignancies. NF-κB family members and their regulated genes have been linked to malignant transformation, tumor cell proliferation, survival, angiogenesis, invasion/metastasis, and therapeutic resistance. In this review, we highlight the diverse molecular mechanism(s) by which the NF-κB pathway is constitutively activated in different types of human cancers, and the potential role of various oncogenic genes regulated by this transcription factor in cancer development and progression. Additionally, various pharmacological approaches employed to target the deregulated NF-κB signaling pathway, and their possible therapeutic potential in cancer therapy is also discussed briefly.
Showing items related by title, author, creator and subject.
Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude miceShanmugam, M.; Rajendran, P.; Li, F.; Nema, T.; Vali, S.; Abbasi, T.; Kapoor, S.; Sharma, A.; Kumar, Alan Prem; Ho, P.; Hui, K.; Sethi, G. (2011)Activation of transcription factors nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) is frequently observed in prostate cancer and has been linked with tumor cell proliferation, ...
CHIP/Stub1 functions as a tumor suppressor and represses NF-?B-mediated signaling in colorectal cancerWang, Y.; Ren, F.; Wang, Y.; Feng, Y.; Wang, D.; Jia, B.; Qiu, Y.; Wang, S.; Yu, J.; Sung, J.; Xu, J.; Zeps, Nikolajs; Chang, Z. (2014)The carboxyl terminus of Hsc70-interacting protein (CHIP, also named Stub1), a U-box containing E3 ubiquitin ligase, is involved in degradation of certain oncogenic proteins. Recent studies indicated that CHIP suppresses ...
Shin, E.; Hay, H.; Lee, M.; Goh, J.; Tan, T.; Sen, Y.; Lim, S.; Yousef, E.; Ong, H.; Thike, A.; Kong, X.; Wu, Z.; Mendoz, E.; Sun, W.; Salto-Tellez, M.; Lim, C.; Lobie, P.; Lim, Y.; Yap, C.; Zeng, Q.; Sethi, G.; Lee, M.; Tan, P.; Goh, B.; Miller, L.; Thiery, J.; Zhu, T.; Gaboury, L.; Tan, P.; Hui, K.; Yip, G.; Miyamoto, S.; Kumar, Alan Prem; Tergaonkar, V. (2014)Despite advancement in breast cancer treatment, 30% of patients with early breast cancers experience relapse with distant metastasis. It is a challenge to identify patients at risk for relapse; therefore, the identification ...